TrialClinical drug investigation2021

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS.

Seth C Hopkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.